Natco Pharma files suit in Delhi High Court seeking revocation of Novo Nordisk's patent on diabetes drug semaglutide. Court issues notice, hearing set for Feb 5. Indian pharma race for generic Ozempic heats up.
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
Hyderabad's Natco Pharma petitions Delhi High Court to revoke Novo Nordisk's semaglutide patent. The legal battle shapes India's future weight-loss drug market as 2026 patent expiry nears. Read more.
Novo Nordisk launches oral Wegovy weight-loss drug in the US, priced at $299. The pill, approved in Dec 2025, aims to regain market share from rival Eli Lilly. UK approval expected end-2026.
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Ant-Man star Evangeline Lilly discloses traumatic brain injury results, revealing decreased brain function. Read her emotional update and road to recovery.
Marvel star Evangeline Lilly reveals traumatic brain injury diagnosis after a 2025 fall. Get the full health update and her recovery journey here.
Marvel star Evangeline Lilly shares a traumatic brain injury diagnosis after a 2025 accident in Hawaii. She details her recovery journey and life reassessment. Read her full story.
Novo Nordisk and Eli Lilly to launch oral GLP-1 drugs in 2026. Despite Novo's head start, analysts predict Lilly's market leadership in obesity and diabetes treatments will persist for years. Explore the details.
US FDA approves Novo Nordisk's daily Wegovy pill, an oral alternative to injections. Priced from $149, it offers 14% average weight loss. Details on cost, side effects, and how it compares to rivals.
Shares of Novo Nordisk surged over 7% after its weight loss drug Wegovy pill received US FDA approval on December 22, 2025. Read the full market impact analysis.
US FDA approves Novo Nordisk's Wegovy Pill, first oral GLP-1 drug for weight loss. Priced at $149/month, it promises wider access and challenges injectable dominance. Read more.
Emcure Pharmaceuticals launches Poviztra, a weekly semaglutide injection for weight loss, in partnership with Novo Nordisk. Priced from ₹2,200 per week, it targets India's massive obesity market.
Emily in Paris star Lucas Bravo opens up about hating small talk, his journey to landing Gabriel's role, and his love for deep conversations about life and growth. Read more!
Australia mourns Rabbi Eli Schlanger as first funeral held for Bondi Beach shooting victims. PM Albanese vows action on antisemitism. Latest updates on the Sydney tragedy.
A Holocaust survivor shielding his wife and a community rabbi are among the 15 victims of the Sydney mass shooting. Read about the heroes and the global tributes.
Delhi High Court rejects Novo Nordisk's patent plea on semaglutide (Ozempic/Wegovy), preventing 'evergreening'. A win for affordable generics in India, but raises concerns over non-clinical misuse of weight-loss drugs. Read more.
Delhi High Court rejects Novo Nordisk's plea for interim injunction against Dr Reddy's Labs over semaglutide. Court cites 'evergreening', allows DRL to export. Key ruling for diabetes drug market.
A recent Delhi High Court order in the Novo Nordisk vs Dr Reddy's case highlights the complexities of Indian patent litigation. We examine the system's challenges and the push for specialized IP courts.
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
Eli Lilly reduces Zepbound's starting price to $299 monthly, intensifying its price war with Novo Nordisk's Ozempic and Wegovy. New discounts aim to expand access to blockbuster weight-loss drugs.
Eli Lilly's oral GLP-1 drug Orforglipron offers needle-free weight management with significant results in Phase 3 trials. Discover how this tablet alternative works.
Exclusive interview with Lilly Singh on sisterhood, digital creators' respect, Hollywood diversity struggles, and why women comedians face unfair criticism. Read her powerful insights!
Eli Lilly's daily pill orforglipron shows 12% weight loss in trials, potentially revolutionizing obesity treatment. Could this be the end of injections?
Novo Nordisk and Eli Lilly develop daily oral weight loss pills with 10-16% average weight loss in trials. Pending FDA approval, these could replace injections.
Missouri Tigers QB Beau Pribula is set to start against Oklahoma Sooners just four weeks after a dislocated ankle injury. Coach Drinkwitz confirms his availability for the pivotal road game.
Eli Lilly makes pharmaceutical history as first company to achieve $1 trillion market capitalization after shares rose 1.7% on November 21, 2025. Learn what this means for investors.
Eli Lilly's Alzheimer's drug donanemab gets Indian regulatory approval. The treatment slows cognitive decline by 35.1% and could be available next year. Learn about its benefits and pricing.
Eli Lilly's Alzheimer's drug donanemab gets Indian regulator nod. The treatment slows cognitive decline by 35.1% and is expected to launch in India next year. Details on pricing and safety.
Novo Nordisk reduces Wegovy's price to $349 and prepares an aggressive launch for its oral weight-loss pill to combat competition from Eli Lilly and expand patient access.